| payload |
{"created_at":"2026-04-18T03:05:05.644 {"created_at":"2026-04-18T03:05:05.644967+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:25c19a536ee051ce","evidence_event_ids":["evt_15b39a1e02d7"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000159.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000159.txt","company":"VERTEX PHARMACEUTICALS INC / MA","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000159.txt","article_chars":1666,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_087d1fb22c03313e","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000159.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:18:37.304350+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000159.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000159.txt","source_event_id":"evt_15b39a1e02d7","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"fca7c931e9bee665","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":["2026-04-15","2026-04-17","2026-04-18T03:05:05.644967+00:00"],"entities":[{"asset_class":"equity","name":"VERTEX PHARMACEUTICALS INC / MA","relevance":"high","symbol":"VRTX","type":"issuer"},{"asset_class":"person","name":"Alan M. Garber","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"person","name":"Garber Alan M","relevance":"medium","symbol":"","type":"reporting_owner_name_variant"}],"event_type":"other","information_gaps":["The cleaned text does not explicitly state whether the deferred stock units were acquired, disposed, or otherwise changed versus a prior state; it only provides the Form 4 content shown.","The signal type is \u201cdiscovery_sec_filing_delta,\u201d but no prior known state or comparison data is included in the provided text, so \u201cwhat changed vs prior\u201d cannot be determined.","The meaning of the numeric fields \u201c33.898\u201d and \u201c442.50\u201d is not fully explained in the provided text (e.g., whether 33.898 is the number of units and 442.50 is a total value).","No transaction code (e.g., acquisition/disposition) or explicit \u201cchange\u201d amount is shown in the provided excerpt beyond the descriptive DSU settlement language."],"key_facts":["SEC accession number: 0000875320-26-000159.","Form type: 4 (Form 4).","Issuer: VERTEX PHARMACEUTICALS INC / MA (CIK shown as 0000875320).","Reporting owner: Garber Alan M (CIK shown as 0001312907).","Conformed period of report: 20260415; filed as of date: 20260417.","The filing includes an entry labeled \u201cDeferred Stock Units\u201d with date 2026-04-15.","The filing states: \u201cEach deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.\u201d","The filing includes a common stock price/amount field shown as \u201c33.898\u201d and \u201c442.50\u201d (exact interpretation of these fields beyond the text is not provided)."],"numeric_claims":[{"label":"Deferred stock units date","value":"2026-04-15"},{"label":"Quantity shown (deferred stock units)","value":"33.898"},{"label":"Value shown","value":"442.50"},{"label":"Filing date (as of date)","value":"2026-04-17"},{"label":"Conformed period of report","value":"2026-04-15"}],"primary_claim":"On 2026-04-17, Vertex Pharmaceuticals filed Form 4 reporting deferred stock units held by Alan M. Garber, with each deferred stock unit representing one share of common stock and payable upon specified events.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Vertex Pharmaceuticals (VRTX) filed a Form 4 on 2026-04-17 for reporting period 2026-04-15 by reporting owner Alan M. Garber. The filing discloses deferred stock units that are settled in common stock upon specified triggering events.","topics":["SEC Form 4","insider transaction disclosure","deferred stock units","common stock settlement","board service termination","change of control","disability or death"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 VERTEX PHARMACEUTICALS INC / MA \u00b7 Filed 20260417","ticker":"VRTX","tickers":["VRTX"],"title":"VRTX filed 4","url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000159.txt"}}... |